Factor VIIa (recombinant) for acute traumatic hemorrhage

American Journal of Health-System Pharmacy

Volumn 65, Issue 17, 2008, Pages 1616-1623

  Patanwala, Asad E ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Factor VIIa; Hemorrhage; Hemostatics; Mortality

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ACUTE HEART INFARCTION; ARTERY THROMBOSIS; BLEEDING; BLUNT TRAUMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ERYTHROCYTE TRANSFUSION; HEMOPHILIA; HEMOSTASIS; HUMAN; INJURY; LUNG EMBOLISM; PENETRATING TRAUMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; STROKE; THROMBOSIS; VEIN THROMBOSIS;

EID: 51649101294     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp080008     Document Type: Review

References (37)

1. Heron M. Deaths: leading causes for 2004. Natl Vital Stat Rep. 2007; 56(5):1-95.
2. Bellamy RF. The causes of death in conventional land warfare: implications for combat casualty care research. Mil Med. 1984; 149:55-62.
3. Sauaia A, Moore FA, Moore EE et al. Epidemiology of trauma deaths: a reassessment. J Trauma. 1995; 38:185-93.
4. Spahn DR, Cerny V, Coats TJ et al. Management of bleeding following major trauma: a European guideline. Crit Care. 2007; 11:R17. [Erratum, Crit Care. 2007; 11:414.]
5. NovoSeven (coagulation factor VIIa [recombinant]) package insert. Princeton, NJ: Novo Nordisk Pharmaceuticals; 1999 Sep.
6. Aitken MG. Recombinant factor VIIa. Emerg Med Australas. 2004; 16:446-55.
7. Schreiber MA. Coagulopathy in the trauma patient. Curr Opin Crit Care. 2005; 11:590-7.
8. Cosgriff N, Moore EE, Sauaia A et al. Predicting life-threatening coagulopathy in the massively transfused trauma patient: hypothermia and acidoses revisited. J Trauma. 1997; 42:857-61.
9. Boffard KD, Riou B, Warren B et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma. 2005; 59:8-15.
10. Dutton RP, McCunn M, Hyder M et al. Factor VIIa for correction of traumatic coagulopathy. J Trauma. 2004; 57:709-18.
11. Felfernig M, for the European rFVIIa Trauma Study Group. Clinical experience with recombinant activated factor VII in a series of 45 trauma patients. J R Army Med Corps. 2007; 153:32-9.
12. Grounds RM, Seebach C, Knothe C et al. Use of recombinant activated factor VII (NovoSeven) in trauma and surgery: analysis of outcomes reported to an international registry. J Intensive Care Med. 2006; 21:27-39.
13. Harrison TD, Laskosky J, Jazaeri O et al. "Low-dose" recombinant activated factor VII results in less blood and blood product use in traumatic hemorrhage. J Trauma. 2005; 59:150-4.
14. Martinowitz U, Kenet G, Lubetski A et al. Possible role of recombinant activated factor VII (rFVIIa) in the control of hemorrhage associated with massive trauma. Can J Anaesth. 2002; 49:S15-20.
15. Martinowitz U, Michaelson M. Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force. J Thromb Haemost. 2005; 3:640-8.
16. Kenet G, Walden R, Eldad A et al. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet. 1999; 354:1879. Letter.
17. Barletta JF, Ahrens CL, Tyburski JG et al. A review of recombinant factor VII for refractory bleeding in nonhemophilic trauma patients. J Trauma. 2005; 58:646-51.
18. Shander A, Goodnough LT, Ratko T et al. Consensus recommendations for the off-label use of recombinant human factor VIIa (NovoSeven) therapy. Pharm Ther. 2005; 30:644-58.
19. Ratko TA. Off-label use of recombinant activated factor VII. Oakbrook, IL: University HealthSystem Consortium; 2004.
20. Mayer SA. Recombinant activated factor VII for acute intracerebral hemorrhage. Stroke. 2007; 38(suppl 2):763-7.
21. Bartal C, Freedman J, Bowman K et al. Coagulopathic patients with traumatic intracranial bleeding: defining the role of recombinant factor VIIa. J Trauma. 2007; 63:725-32.
22. Kluger Y, Riou B, Rossaint R et al. Safety of rFVIIa in hemodynamically unstable polytrauma patients with traumatic brain injury: post hoc analysis of 30 patients from a prospective, randomized, placebo-controlled, double-blind clinical trial. Crit Care. 2007; 11:R85.
23. Roberts HR, Monroe DM 3rd, Hoffman M. Safety profile of recombinant factor VIIa. Semin Hematol. 2004; 41(1, suppl 1):101-8.
24. O'Connell KA, Wood JJ, Wise RP et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006; 295:293-8.
25. Thomas GO, Dutton RP, Hemlock B et al. Thromboembolic complications associated with factor VIIa administration. J Trauma. 2007; 62:564-9.
26. Stein DM, Dutton RP, O'Connor J et al. Determinants of futility of administration of recombinant factor VIIa in trauma. J Trauma. 2005; 59:609-15.
27. Meng ZH, Wolberg AS, Monroe DM 3rd et al. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J Trauma. 2003; 55:886-91.
28. Watts DD, Trask A, Soeken K et al. Hypothermic coagulopathy in trauma: effect of varying levels of hypothermia on enzyme speed, platelet function, and fibrinolytic activity. J Trauma. 1998; 44:846-54.
29. Klitgaard T, Palacios R, Boffard KD et al. Pharmacokinetics of recombinant activated factor VII in trauma patients with severe bleeding. Crit Care. 2006; 10:R104.
30. Vincent JL, Rossaint R, Riou B et al. Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding - a European perspective. Crit Care. 2006; 10:R120.
31. Bauza G, Hirsch E, Burke P et al. Low-dose recombinant activated factor VII in massively transfused trauma patients with coagulopathy. Transfusion. 2007; 47:749-51.
32. Bloomfield R, Steel E, MacLennan G et al. Accuracy of weight and height estimation in an intensive care unit: implications for clinical practice and research. Crit Care Med. 2006; 34:2153-7.
33. Goodnough LT, Shander AS. Recombinant factor VIIa: safety and efficacy. Curr Opin Hematol. 2007; 14:504-9.
34. Red book 2007: pharmacy's fundamental reference. Montvale, NJ: Thompson Healthcare; 2007:587.
35. Morris S, Ridley S, Munro V et al. Cost effectiveness of recombinant activated factor VII for the control of bleeding in patients with severe blunt trauma injuries in the United Kingdom. Anaesthesia. 2007; 62:43-52.
36. ClinicalTrials.gov. Evaluation of recombinant factor VIIa in patients with severe bleeding due to trauma. www.clinicaltrials.gov/ct2/show/NCT00323570 (accessed 2007 Dec 20).
37. ClinicalTrials.gov. The use of rFVIIa in trauma patients: a multi-center case registry. www.clinicaltrials.gov/ct2/show/NCT00328133 (accessed 2007 Dec 20).